Arcturus Therapeutics Holdings Inc.
No SEC Form 4 filings for $ARCT in the last 30 days.
See all $ARCT insider activity →Arcturus Therapeutics (Nasdaq: ARCT) terminated its sa-mRNA vaccine partnership with CSL Seqirus via a settlement. Arcturus regained global rights to KOSTAIVE (ARCT-154) and other vaccine programs. CSL Seqirus will pay $12m cash, and Arcturus is released from about $16m in R&D credits, totaling about $28m. The deal unwinds a pact valued around $4.3b.
Arcturus Therapeutics Holdings Inc. (ARCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 e665679_ex99-1.htm Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrol
Arcturus Therapeutics (ARCT) shares rose 7.84% to $7.43 on Nasdaq after the company said it entered a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis. Thermo Fisher will provide manufacturing, clinical research and commercialization support via its Accelerator platform, with exclusive commercial manufacturing rights if approved.
Over the past 7 days, alphai's AI scored 2 news stories mentioning ARCT (Arcturus Therapeutics Holdings Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent ARCT coverage spans mergers & acquisitions, financial news and corporate actions.
Portfolio reversion plus a $12M cash receipt and release from ~$16M R&D credit liabilities changes near-term economics and removes a commercial partner for KOSTAIVE outside Meiji Seika’s carve-out.
Near-term catalyst is the disclosed Phase 2 progress plus a later-quarter data and regulatory plan update; balance-sheet support improves risk appetite.
The Thermo Fisher Accelerator Drug Development deal is a concrete execution/capability milestone for ARCT-032, likely supporting near-term sentiment and optionality on Phase 3 progress.
De-risks ARCT-032’s path to Phase 3 by securing manufacturing/clinical execution support and a conditional commercialization manufacturing framework.
Deal terms and manufacturing/commercial-readiness support are a near-term catalyst for ARCT-032 execution risk and potential approval upside.
alphai scores every news story that mentions ARCT with an AI model for sentiment and relevance, and aggregates insider trades from Arcturus Therapeutics Holdings Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Arcturus Therapeutics (Nasdaq: ARCT) terminated its sa-mRNA vaccine partnership with CSL Seqirus via a settlement. Arcturus regained global rights to KOSTAIVE (ARCT-154) and other vaccine programs. CSL Seqirus will pay $12m cash, and Arcturus is released from about $16m in R&D credits, totaling about $28m. The deal unwinds a pact valued around $4.3b.
4 min readArcturus Therapeutics Holdings Inc. (ARCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 e665679_ex99-1.htm Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrol
6 min readArcturus Therapeutics (ARCT) shares rose 7.84% to $7.43 on Nasdaq after the company said it entered a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis. Thermo Fisher will provide manufacturing, clinical research and commercialization support via its Accelerator platform, with exclusive commercial manufacturing rights if approved.
2 min readArcturus Therapeutics said it selected Thermo Fisher Scientific to support Phase 3 development of ARCT-032, an inhaled mRNA therapy for cystic fibrosis. Thermo Fisher will provide Phase 3 manufacturing and clinical research services, with Phase 3 expected to run via Thermo Fisher’s PPD if Phase 2 is positive. A separate deal could grant exclusive commercial manufacturing rights if ARCT-032 is approved. Arcturus shares were up 12.19% to $7.73.
3 min readArcturus Therapeutics (NASDAQ:ARCT) rose 5.8% premarket after announcing a collaboration with Thermo Fisher Scientific (NYSE:TMO) for late-stage development and commercialization support of ARCT-032, an experimental mRNA cystic fibrosis treatment. Thermo Fisher will provide manufacturing and clinical research services; Arcturus expects to use Thermo Fisher’s clinical research business if mid-stage data are positive and grants exclusive commercial manufacturing rights if approved.
3 min readArcturus Therapeutics Holdings Inc. (ARCT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001768224 0001768224 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
4 min readArcturus Therapeutics Holdings Inc. (ARCT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001768224 0001768224 2026-06-05 2026-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readArcturus Therapeutics highlights the critical role of phased clinical trials in bringing new gene and cell therapies from scientific discovery to patient treatments. The company emphasizes that each phase provides essential insights into safety and effectiveness, supported by ongoing collaborations to advance rare disease solutions and reports on financial standing and pipeline progress. This rigorous approach ensures promising treatments are thoroughly vetted before market entry.
3 min readArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) discussed its Q4 2025 earnings, reporting an EPS miss. The call focused on the advancement of its mRNA therapeutic candidates, ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase deficiency, highlighting progress in clinical trials and regulatory interactions. The company also provided updates on its partnered COVID-19 vaccine program and its financial position, including a cash runway extended into Q2 2028.
3 min readArcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +60.80% and +50.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min read
